GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD) Trial also met its first key secondary

Related Keywords

Canada ,Florida ,United States ,Sweden ,New Jersey ,Missouri ,Massachusetts ,American ,Tim Bateman ,Debbie Leven ,Francois Tranquart ,Mark Kinarney ,Centers For Disease ,Linkedin ,Twitter ,Global Head Of Clinical Development ,Corporate Communications ,Facebook ,Lantheus Holdings Inc ,American Society Of Nuclear Cardiology ,Ge Healthcare ,Coronary Artery Disease ,Perfusion Imaging ,Molecular Imaging ,American Society ,Nuclear Cardiology ,Positron Emission Tomography ,Single Photon Emission Computed Tomography ,Myocardial Perfusion Imaging ,Open Label Study ,Cardiovascular Radiologic Imaging Program ,Saint Luke ,Global Head ,Clinical Development ,Pharmaceutical Diagnostics ,Global Epidemiology ,Ischemic Heart Disease ,Global Burden ,Disease Control ,Heart Disease ,Accessed July ,Media Contact ,Investor Relations ,Healthcare ,Lantheus ,Hase ,Linical ,Trial ,Kinds ,Lurpiridaz ,Radiotracer ,Would ,Mprove ,Detection ,Coronary ,Artery ,Disease ,